In this study, we report that the migration of breast and squamous carcinoma cells toward either lysophosphatidic acid or epidermal growth factor involves not only phosphodiesterase activity but also cooperative signaling from PKA. Furthermore, we demonstrate that Rac1 activation in response to chemoattractant or ␤ 1 integrin clustering is regulated by PKA and that Rac1 is required for this migration. Also, we find that ␤ 1 integrin signaling stimulates the rapid and transient activation of PKA. A novel implication of these findings is that carcinoma cell migration is controlled by cAMP-dependent as well as cAMP inhibitory signaling mechanisms.
Cell migration in response to growth factors and chemoattractants is essential for embryonic development, tissue homeostasis, and the immune response (1) . It is also a major factor in the pathogenesis of many human diseases, including cancer (2) . This complex process involves dynamic and coordinated interactions among integrins, chemoattractant receptors, and the actin cytoskeleton, which result in actin polymerization at the leading edge and contraction of actin bundles within the cell body to promote translocation. These dynamic changes in the actin cytoskeleton are initiated by the engagement of chemoattractant and integrin receptors on the cell surface with the respective ligands. Such interactions trigger cascades of signaling events that result in the remodeling of the actin cytoskeleton and consequent directed movement (3) . To understand cell migration at a mechanistic level, these signaling events need to be defined and linked to both cell surface receptors and actin dynamics. Members of the Rho family of GTPases, including Rho, Rac, and Cdc42 in particular, are considered to be key signaling intermediates for cell migration (1, 4 -8) . These GTPases are activated by signaling pathways initiated at the cell surface and in their activated or GTP-bound state stimulate downstream effectors that regulate actin polymerization and actin-myosin contraction (1, 9) . Despite considerable progress in understanding the function of the Rho GTPases, the mechanisms by which its activities are regulated by cell surface receptors and how this regulation relates to cell migration are unclear (10) .
Recent studies have highlighted an important role for cAMP metabolism in the migration of carcinoma cells and in the regulation of RhoA function. Specifically, we found that cAMPspecific phosphodiesterases (PDEs) 1 facilitate carcinoma cell migration as well as lamellae formation by lowering cAMP levels (11) . More mechanistic studies have revealed that cAMP inhibits RhoA activity (8, (12) (13) (14) , which has been shown to be required for carcinoma migration and invasion (8, 15, 16) . In fact, based on these observations, the current study was initiated to test the hypothesis that PKA activity inhibits carcinoma cell migration. Surprisingly, we observed that chemoattractant-stimulated migration requires PKA activity as well as PDE activity. In other terms, our results infer that this migration is controlled by cAMP-dependent as well as cAMP inhibitory signaling mechanisms. We provide an explanation for this paradox by demonstrating that PKA is required for Rac activation by chemoattractants as well as ␤ 1 integrins, a function that contrasts with its inhibition of RhoA. An important implication of these findings is that localized fluctuations in the intracellular concentration of [cAMP] i may provide a spatial and temporal regulation of PKA activity that influences Rac and RhoA function.
EXPERIMENTAL PROCEDURES
Cells-MDA-MB-435 human breast carcinoma cells were obtained from the Lombardi Breast Cancer Depository at Georgetown University. A431 squamous carcinoma cells were obtained from the American Type Culture Collection. Cells were cultured in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal calf serum plus 1% L-glutamine, 1% penicillin, and 1% streptomycin (Invitrogen). For each experiment, subconfluent cell cultures were harvested with trypsin and rinsed with either DMEM or RPMI 1640 medium containing 250 g/ml heat-inactivated BSA (DMEM/BSA and RPMI 1640/BSA, respectively).
Migration Assays-Migration assays were performed as described previously (11) . Briefly, Transwell chamber membranes (6.5-mm diameter, 8-m pore size; Costar) were coated with 15 g/ml collagen I (Vitrogen, Collagen Biomaterials). Lysophosphatidic acid (LPA; 100 nM; Sigma) or epidermal growth factor (EGF; 5 ng/ml; Sigma) was added to the lower chambers. Cells (5 ϫ 10 4 ) were added to the upper chamber and allowed to migrate for 4 h at 37°C. Cells that had not migrated were removed from the upper chamber with a cotton swab. The remaining cells were fixed, stained with crystal violet, and counted as described previously (11) . In some experiments, the pharmacological inhibitors H-89, IBMX, and a myristoylated peptide derivative of PKI (Calbiochem) were added to the cell suspensions for 30 min before the cells were added to the wells. For checkerboard analysis of migration, LPA was placed in the bottom and/or top chambers of the Transwells as noted and then cells were added to the top chamber and assessed for migration as described above.
The involvement of Rac1 in migration was assessed using a dominant negative construct (N17Rac1). Briefly, cells were electroporated (8) with 1 g of pCS2-(n)␤-gal and 4 g of either control vector or GST-tagged N17Rac1 construct (obtained from Chris Carpenter, Beth Israel Deaconess Medical Center) at 250 V and 500 microfarads. Cells were then cultured in growth medium containing 0.05% sodium butyrate for 16 h and assayed for LPA-or EGF-stimulated migration 48 h after the initial transfection as described above. N17Rac1 expression was confirmed by concentrating extracts of transfected cells with glutathione-coupled Sepharose 4B beads (Amersham Biosciences) and immunoblotting for Rac1 (mouse mAb; BD Transduction Laboratories).
Rac Activity Assays-Rac activity assays were based on established protocols (6, 17) . For these experiments, serum-starved cells (3 ϫ 10 6 ) were treated with 8 g of anti-integrin ␤ 1 mouse mAb MC13 (obtained from Steve Akiyama, National Institutes of Health, Research Triangle Park, NC) for 30 min at room temperature. Cells were then pelleted, resuspended in RPMI 1640/BSA, and either plated onto goat antimouse IgG-coated (50 g; Jackson Immunochemicals) 60-mm dishes or left in suspension. Cells were incubated at 37°C for the indicated time periods and then harvested with 50 mM Tris, pH 7.4, 100 mM NaCl, 1% Nonidet P-40, 10% glycerol, 2 mM MgCl 2, 10 g/ml leupeptin, 10 g/ml aprotinin, 1 g/ml pepstatin, and 1 mM phenylmethylsulfonyl fluoride. Cell extracts were cleared by centrifugation, and 10% of the total volume was used for assessment of the total Rac content. The remaining extract was combined with 2 volumes of binding buffer (25 mM Tris, pH 7.5, 1 mM dithiothreitol, 40 mM NaCl, 30 mM MgCl 2 , 0.5% Nonidet P-40) and the bacterially produced Rac/Cdc42 binding domain of Pak (PBD)-GST fusion protein (obtained from Rick Cerione, Cornell University, Ref. 17) coupled to glutathione beads and was then incubated for 30 min at 4°C. Beads were then rinsed three times with binding buffer and eluted in 2ϫ Laemmli sample buffer. Aliquots of both total cell extracts and the eluents from the PBD beads were immunoblotted for Rac1.
To assess the impact of chemoattractants on Rac activation, cells were plated onto collagen-coated dishes in RPMI 1640/BSA and allowed to attach and spread for 2-4 h. Prior to chemoattractant stimulation, cells were treated with either carrier, 15 M H-89, 1 M PKI, or 1 mM IBMX for 30 min or with either the ␤ 1 integrin-specific mAb MC13 or control IgG for 5 min. Cells were then treated with chemoattractant (5 ng/ml EGF or 100 nM LPA) for 10 min unless indicated otherwise. Subsequently, cell extracts were assessed for Rac activity as described above.
PKA Assays-For the PKA assays, cells were subjected to antibodymediated clustering of either ␤ 1 integrins or a major histocompatibility complex (using anti-human leukocyte antigen class I mAb, Sigma) or left in suspension as described above and harvested with a 50 mM Tris buffer, pH 7.5, containing 5 mM EDTA, 50 mM NaF, 1 mM sodium pyrophosphate, and protease inhibitors. Cell extracts were sonicated, and debris was removed by centrifugation. Extracts were incubated for 5 min at 30°C in reaction buffer (final concentration was 50 mM Tris, pH 7.5, 10 mM MgCl 2 , 100 M ATP, 4nmol of [␥-32 P]ATP, 0.25 mg/ml BSA, and 50 M Leu-Arg-Arg-Ala-Ser-Leu-Gly (Kemptide; Invitrogen) either alone (control) or in the presence of either 1 M PKI peptide (background), 10 M cAMP (total PKA activity), or PKI plus cAMP (total background activity). Samples were assayed in triplicate for each condition and quantified on a scintillation counter. PKI-inhibitable kinase activity was calculated, and the data were reported as percent of total PKA activity.
RESULTS

LPA-stimulated Migration Requires
Both PKA and PDE Activities-PKA is activated in response to cAMP generated by adenyl cyclases (18) . We hypothesized that PKA is inhibitory for carcinoma cell migration based on our previous findings that chemotaxis requires PDE activity and that it is promoted by increasing PDE activity and reducing [cAMP] i levels (11). To test this hypothesis, we assessed the migration of MDA-MB-435 breast carcinoma cells toward LPA in the presence or absence of the PKA-specific inhibitor, H-89. Checkerboard analysis indicated that this migration is predominantly chemokinetic (Fig. 1C) . Surprisingly, treatment of these cells with concentrations of H-89 known to be specific for PKA in vivo (19) resulted in a concentration-dependent inhibition of migration (Fig. 1A) . These concentrations of H-89 resulted in a dose-dependent decrease in total recoverable PKA activity (data not shown). The inhibitory effects of H-89 were confirmed using a myristoylated, cell-permeable peptide derivative of the naturally occurring PKA inhibitor (Fig. 1B, PKI) .
The above results implicate PKA activity as a critical component of MDA-MB-435 chemokinesis. Together with our previous findings on PDEs (11), these results suggest that chemoattractant-induced migration may involve both cAMPdependent and cAMP inhibitory signaling mechanisms. To determine whether PDEs and PKA function either cooperatively were then assayed for migration toward 100 nM LPA in the continued presence of these inhibitors using a Transwell chamber assay as described under "Experimental Procedures." B, cells were treated with either 1 M myristoylated cell permeable peptide derivative of PKI or 15 M H-89 and then assayed for migration as described above. C, LPA (100 nM) was placed in either the bottom, top, or both chambers of the Transwells as noted. or antagonistically in migration, cells were treated with suboptimal concentrations of both IBMX and H-89 prior to their use in the migration assay. As expected from our previous studies (8, 11) , the PDE inhibitor IBMX blocked the LPAstimulated migration of MDA-MB-435 cells (Fig. 1A and Ref. 11). Interestingly, the combined inhibitory effects of IBMX and H-89 treatment on migration were additive rather than compensatory. Collectively, these data emphasize the importance of PKA in migration and indicate that cAMP-dependent as well as cAMP inhibitory signaling mechanisms work in a cooperative manner to regulate chemoattractant-induced migration of carcinoma cells.
Rac Activation by ␤ 1 Integrins Requires PKA-The small GTPase Rac is necessary for the migration and invasion of carcinoma cells (4 -6), including MDA-MB-435 ( Fig. 2A and  Ref. 4) . Based on the findings that Rac and Rho often differ in their function and regulation and that cAMP impedes Rho function, we sought to determine whether PKA activity is required for Rac activation in MDA-MB-435 cells.
First, we examined the involvement of LPA and integrins in Rac activation. For these experiments, we utilized the Rac/ Cdc42 binding domain (CRIB) of Pak fused to GST to affinity precipitate activated Rac (Rac assay) as described previously (6, 17) . In agreement with a previous report (20) , we observed that Rac is activated in response to LPA. As shown in Fig. 2C , LPA stimulated a rapid and transient activation of Rac that peaked within 10 min of stimulation. Interestingly, this activation was blocked by the addition of a ␤ 1 integrin-specific mAb (Fig. 2C) , indicating that the LPA stimulation of Rac is dependent on ␤ 1 integrins. The addition of this mAb did not perturb the attachment of the cells to matrix (data not shown). Most likely, it prevented the formation of new ␤ 1 integrin contacts in response to LPA.
Next, we assessed activation of Rac by integrin signaling. As shown in Fig. 3A , antibody-mediated clustering of ␤ 1 integrins induced a time-dependent activation of Rac that was maximal at 30 min. Importantly, inhibition of PKA activity with either H-89 (Fig. 3B) or PKI (Fig. 3C) prevented Rac activation by ␤ 1 clustering. These PKA inhibitors did not interfere with cell attachment to the antibody-coated wells (data not shown). Furthermore, the PDE inhibitor IBMX had no effect on the activation of Rac by ␤ 1 integrin ligation (data not shown). These results indicate that Rac activation in response to the clustering of ␤ 1 integrins requires PKA activity.
FIG. 2.
A, LPA-stimulated migration of MDA-435 cells requires Rac. Cells that had been cotransfected with a ␤-galactosidase construct and either control vector or GST-tagged N17Rac were assayed for LPAstimulated migration as described in the legend to Fig. 1 . Cells that had migrated were fixed and stained for ␤-galactosidase. Transfected, ␤-galactosidase positive cells were counted and reported as the relative number of cells migrated compared with the vector control. Bars represent means Ϯ S.E. of triplicate determinations. The p value for control versus N19 Rac ϭ 0.02. B, transgene expression was confirmed by precipitating GST-Rac1 from extracts of cells from A with glutathione beads and immunoblotting for Rac1. C, LPA stimulation of Rac activation is dependent on ␤ 1 integrins. Cells were plated onto collagencoated dishes and allowed to attach and spread. Subsequently, either the ␤ 1 integrin-specific mAb MC13 or a control IgG was added to the cells for 5 min, and the cells were then stimulated with 100 nM LPA for the indicated period of time. Cell extracts were assessed for Rac activity using the PBD assay as described under "Experimental Procedures." Representative experiments are shown.
FIG. 3. Rac activation by ␤ 1 integrins requires PKA. A and B,
antibody-mediated clustering of ␤1 integrins was performed as described under "Experimental Procedures" either in the presence (A) or absence (B) of 15 M H-89 for the times indicated. Cell extracts were assayed for Rac activation using the PBD assay as described under "Experimental Procedures." C, antibody-mediated clustering of ␤ 1 integrins was performed in either the presence or absence of the PKI peptide for 30 min, and cell extracts were assayed for Rac activity as described above. Upper panels, Rac bound to the PBD; Lower panels, total Rac expressed in cell extracts.
␤ 1 Integrin Signaling Stimulates PKA Activity-In response to a chemoattractant such as LPA, new ␤ 1 integrin-mediated contacts are formed at the leading edge to generate the traction necessary for migration (1, 21) . Given that both ␤ 1 integrins (11) and PKA ( Fig. 1) are required for cell migration on collagen, we tested the possibility that ␤ 1 integrin signaling stimulates PKA activation. To address this hypothesis, ␤ 1 integrins were clustered with a specific mAb for varying periods of time, and cell extracts were assayed for PKA activity (Fig. 4) . As shown in Fig. 4A , mAb-mediated clustering of ␤ 1 integrins resulted in a rapid, 3-fold activation of PKA that decayed to baseline levels by 30 min. The specificity of this response was confirmed by the finding that clustering MHC 1 molecules, which are expressed on the surface of MDA-MB-435 cells at levels comparable with ␤ 1 integrins (data not shown), did not stimulate PKA activity (Fig. 4B) . These data suggest that ␤ 1 integrin signaling is a potential source of PKA activation required for chemotactic migration.
EGF-stimulated Chemotactic Migration and Rac Activation Also Requires PKA-To extend the results obtained with MDA-MB-435 cells, we used another model of carcinoma cell migration that involves chemotaxis rather than chemokinesis. A431 cells are derived from a squamous carcinoma and chemotax efficiently toward low concentrations of EGF (Fig. 5 and Refs. 22, 23) . Similar to the results obtained with MDA-MB-435 cells, the chemotaxis of A431 cells toward EGF was sensitive to the inhibition of PDE and PKA activities by IBMX and H-89, respectively (Fig. 5A) . Furthermore, A431 cell chemotaxis also required functional Rac (Fig. 5B) as determined by the expression of a dominant negative mutant.
EGF stimulation of A431 cells results in the activation of Rac as assessed by the Pak binding assay (Fig. 6) . In support of our hypothesis that PKA is required for Rac activation, we observed that pretreatment of cells with either H-89 (Fig. 6A) or PKI (data not shown) inhibited EGF-mediated Rac activation. In contrast, the PDE inhibitor IBMX had little effect on Rac activation (Fig. 6A) . Together, these data substantiate the importance of PKA in chemoattractant-induced migration, which includes both chemotaxis and chemokinesis, and in the regulation of Rac. DISCUSSION Recently, we established the importance of cAMP-dependent PDEs in the migration of carcinoma cells (8, 11) . This PDE activity is needed to lower cAMP levels within the cell and facilitate activation of RhoA. In our current study, we show that either LPA-or EGF-stimulated migration involves not only cAMP-inhibitory signaling that requires PDE activity but also a cAMP-dependent mechanism mediated by PKA that involves Rac. Importantly, we find that the activation of Rac in carcinoma cells in response to either chemoattractant stimula- Our results represent the first direct evidence that Rac activation can be controlled by cAMP/PKA. This finding is supported by other reports that have indirectly implicated Rac as a target of PKA. For example, PKA is necessary for cadherinmediated cell-cell adhesion in epithelial cells (24) , a process that is dependent on Rac (25) . Also, Rac was shown to be an intermediate in the PKA-dependent activation of p38 mitogenactivated protein kinase (p38 MAPK) in response to thyroidstimulating hormone (26) . Here, we find that PKA is required for the Rac-dependent migration of carcinoma cells. In our study, we demonstrated that Rac activation in response to either ␤ 1 integrin clustering or chemoattractant stimulation is blocked by pharmacological inhibitors of PKA and not by inhibition of phosphodiesterases. In support of this link between PKA and Rac activation, we reported that the Rac-independent migration of clone A colon carcinoma cells does not require PKA (8) .
An important implication of our findings is that PKA can contribute to the differential regulation of the Rac and Rho small GTPases. Recent studies (7) have indicated a reciprocal relationship between Rac and Rho activation and have provided evidence that Rac can inhibit Rho activity. Our data suggest that increased PKA activity would facilitate Rac activation and impede Rho activation and vice versa, thus facilitating their reciprocal relationship. We and others have shown that cAMP/PKA-mediated signaling has an inhibitory effect on RhoA activity (8, (12) (13) (14) . The basis for this inhibition involves the direct phosphorylation of RhoA by PKA (12, 13) . The mechanism by which PKA stimulates Rac activation, however, is unlikely to involve its direct phosphorylation because Rac does not contain a consensus PKA phosphorylation site. PKA may regulate Rac indirectly by modifying the function of molecules that control Rac activation. For example, both Tiam-1 and Trio, which are guanine nucleotide exchange factors involved in Rac activation, have consensus PKA phosphorylation sites. Interestingly, Tiam-1 has been shown to be a target of LPA signaling (27) and, therefore, may provide a link between PKA and Rac activation.
The PKA dependence of Rac activation in the cells we examined contrasts with the reported PKA-mediated inhibition of Pak1 (28) . Pak1, which is a downstream effector of both Rac and Cdc42 (29) , has been implicated in migration (30 -32) . One explanation for this discrepancy is that Rac activation may require only a transient burst of PKA activity, a possibility that is supported by our data on PKA activation in response to ␤ 1 integrin clustering. The transient nature of PKA activation may permit Pak to be activated after complete Rac activation and diminution of PKA activity. Clearly, however, more studies are needed to understand the contribution of PKA to the regulation of Rac and Pak1 activation.
Recent studies by our group and others have revealed that integrins are involved in the regulation of [cAMP] i and PKA activity (11, 24, 28, 33, 34) . Moreover, our finding that ␤ 1 integrins can activate PKA is in agreement with studies in other systems (24, 33) . Most likely, ␤ 1 integrin signaling stimulates adenyl cyclase activity and, consequently, a localized rise in [cAMP] i that increases PKA activity. Given the established importance of heterotrimeric (ht) G proteins in adenyl cyclase activation and cAMP signaling, integrin-mediated PKA activation could be facilitated by heterotrimeric G proteins. In fact, several recent studies have provided evidence that supports this possibility. For example, mechanical stresses applied to the cell surface stimulate cAMP signaling by modulating local release of signals generated by activated integrins in a G protein-dependent manner (33) . Also, the ␣ v ␤ 3 integrin has been reported to activate ht-G i by forming a complex with the integrin-associated protein CD47.
An important conclusion from our experiments involving pharmacological inhibition of PDE and PKA is that these enzymes, whose activities are counter-opposed, function cooperatively to promote chemotactic migration. Their ability to signal cooperatively implies that these enzymes have distinct functions in migration. We suggest that they function together to create microgradients of cAMP/PKA within a cell that are important for migration. This hypothesis is supported by the finding that localized gradients of the [cAMP] i regulate growth cone movement (35) . The formation of cAMP/PKA gradient within migrating cells may differentially influence Rac and Rho, resulting in spatial and temporal differences in the activation of Rac and Rho. Such differences could be manifested, for example, in the Rac-mediated lamellipodial protrusion and Rho-mediated contractility necessary for migration (1, 29) .
PKA regulation of Rac activation may have another important consequence for directed migration. It has been argued that the attractant gradient across a migrating cell is insufficient to signal directionality and that the chemotactic signals at the leading edge need to be amplified to orient and polarize a cell (36) . Our results suggest that PKA signaling may provide one mechanism for amplifying chemotactic signals. During chemotaxis, new ␤ 1 integrin contacts are formed at the leading edge of the cell in response to a chemoattractant gradient. It can be hypothesized that these new integrin contacts stimulate PKA and, as a consequence, amplify Rac activation. This scenario implies that activated Rac is localized at the leading edge of migrating cells. In fact, activated Rac has been localized at the leading edge of migrating cells using fluorescence reso- nance energy transfer (FRET) technology (37) . Furthermore, Rac1 has been implicated in orienting Dictyostelium (38) and lymphocytes (39) during chemotaxis. In this context, it is worth noting that the activation of ␤ 1 integrins leads to the recruitment and colocalization of a PKA regulatory subunit with integrin complexes and the subsequent activation of PKA (24) . In summary, our findings highlight the importance of cAMP and PKA in the regulation of small GTPase function and migration and identify important venues for future work.
